Short answer
Neuronetics, Inc. (STIM) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). November 4, 2026 press release announces Neuronetics’ third-quarter and nine-month 2026 financial results.
Neuronetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- November 4, 2026 press release announces Neuronetics’ third-quarter and nine-month 2026 financial results
- Results cover the three and nine months ended September 30, 2026
- Investor focus: accompanying press release for revenue, profitability, cash flow and guidance details
Item 7.01 · Regulation FD Disclosure
- Investor presentation released November 4, 2026, likely updating business outlook and strategic messaging
- Presentation may include fiscal 2026 expectations for revenue, expenses and growth
- Key monitoring risks: Greenbrook TMS transaction, credit facility terms and ability to achieve positive cash flow
- NeuroStar demand remains dependent on reimbursement, physician adoption and competitive therapies
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $42.0M, up 12.5% YoY, led by Greenbrook revenue growth of 20.1% to $26.2M
- Gross margin expanded to 52.2% from 45.9%, while operating expenses fell 13% to $21.3M
- Adjusted EBITDA turned positive at $1.9M versus $(4.7)M, with net loss narrowing to $1.6M from $9.4M
- Cash from operating and investing activities reached $0.8M, but total cash declined to $27.9M from $34.1M at December 31, 2025
- FY 2026 revenue guidance unchanged at $160M-$164M, while gross margin and operating expense outlook improvedેણ
Item EX-99.2 · Exhibit EX-99.2
- FY 2026 revenue guidance $160M-$164M, representing 7%-10% YoY growth
- Gross margin target 49%-50%, with operating expenses $92.5M-$95.5M
- Operating cash flow and investing guidance $(10.0)M to $(12.0)M, signaling continued cash consumption
- Platform reach: 261,591 patients treated and 9,446,469 treatments administered as of September 30, 2026
- Greenbrook expands access to TMS and Spravato across 93 clinics and 800+ NeuroStar customer sites, with potential psychedelic-therapy upside pending FDA approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neuronetics, Inc. 8-K filings
Get the next STIM 8-K as it lands
Follow STIM for push alerts, or ask the research agent what this filing means.